N※N

Illinois Invests $230M in Plasma Therapy Plant

  //science-technology.news-articles.net/content/2 .. linois-invests-230m-in-plasma-therapy-plant.html
  Published in Science and Technology on Tuesday, March 17th 2026 at 3:10 GMT by CBS News
      Locale: UNITED STATES

CHICAGO, IL - March 17, 2026 - Illinois Governor J.B. Pritzker today unveiled a landmark $230 million investment in a cutting-edge plasma therapy manufacturing plant set to be located in the Chicago metropolitan area. The project, a strategic partnership between global healthcare giant Grifols and Chicago-based logistics specialist CSafe, promises to inject over 200 new jobs into the local economy while significantly strengthening Illinois' position as a national leader in biomanufacturing and life-saving therapeutic production.

The new facility will focus on the crucial process of fractionating plasma - separating blood plasma into its component proteins - to create a range of therapies used to treat individuals suffering from immune deficiencies, bleeding disorders, and a host of other critical conditions. Plasma-derived therapies are increasingly vital in modern medicine, serving as essential treatments for rare and chronic illnesses where no alternatives exist. Demand for these therapies is projected to continue growing in the coming years, driven by an aging population and advancements in diagnostic capabilities.

"This isn't simply about bricks and mortar," Governor Pritzker stated during the announcement. "This investment represents a commitment to the health and wellbeing of patients not just in Illinois, but across the nation. It's about ensuring access to vital therapies and fostering a thriving biomanufacturing ecosystem right here in our state."

Grifols, a Spanish multinational company and a world leader in the development, manufacture, and marketing of plasma-derived therapies, brings decades of expertise and a robust portfolio of products to the partnership. They operate a vast network of plasma donation centers and manufacturing facilities globally, and this new Chicago-area plant will be a key component in expanding their North American production capacity. Grifols has been increasingly focused on expanding its US footprint, recognizing the significant growth potential and favorable business environment offered by states like Illinois.

CSafe, known for its innovative cold chain solutions for the pharmaceutical industry, will play a critical role in ensuring the integrity and temperature control of the highly sensitive plasma and finished therapies throughout the manufacturing process and distribution network. Their expertise in maintaining precise temperature ranges is paramount in preserving the efficacy and safety of these life-saving products. CSafe's local presence and established infrastructure were crucial factors in securing the plant's location within Illinois.

The economic impact of the plant extends beyond the direct job creation. The facility is expected to generate significant ripple effects throughout the regional economy, boosting demand for supporting services such as transportation, logistics, and raw materials. Illinois has actively cultivated a pro-business environment to attract companies like Grifols and CSafe, offering a skilled workforce, robust infrastructure, and a supportive regulatory landscape. This investment builds upon existing initiatives aimed at expanding the state's biopharmaceutical sector, including workforce development programs and research grants.

This project underscores a broader national trend of reshoring pharmaceutical manufacturing. For years, the U.S. relied heavily on foreign sources for critical drugs and therapies. However, recent supply chain disruptions, heightened geopolitical tensions, and a growing focus on national security have spurred efforts to bring manufacturing back home. Illinois is positioning itself as a central hub in this reshoring movement, attracting investment in advanced manufacturing technologies and building a resilient domestic supply chain.

Experts predict that the demand for plasma-derived therapies will continue to outpace supply in the coming years. Conditions like Alpha-1 Antitrypsin Deficiency, Hemophilia, and Primary Immunodeficiency Disorders require ongoing plasma protein therapies, and the number of diagnosed cases is steadily increasing. The new Illinois plant will help address this critical need, ensuring that patients have access to the therapies they require to live healthy and productive lives.

The plant's location within the Chicago area provides access to a highly skilled labor pool, a strong transportation network, and a collaborative ecosystem of research institutions and healthcare providers. Construction is slated to begin in late 2026, with full operational capacity expected by early 2028. The project represents a significant win for Illinois, solidifying its role as a national leader in biomanufacturing and a vital contributor to the health and wellbeing of patients worldwide.